Hemorise 500 IV Injection

About Hemorise 500 IV 500 mg/10 ml Injection

The injection Hemorise 500 IV contains Ferric Carboxymaltose and is made by The ACME Laboratories Ltd. It is intended for people who do not tolerate iron taken by mouth or who have not had a satisfactory response to oral iron.

There are 15 brands of Ferric Carboxymaltose listed in Bangladesh. The lowest listed price is Ferium Injection 500 mg/10 ml at ৳ 700 per unit.

What is Hemorise 500 IV 500 mg/10 ml Injection?

Hemorise 500 IV 500 mg/10 ml injection is a medicine made by The ACME Laboratories Ltd. When body iron stores fall, anaemia can develop. It is given by a healthcare professional, not by the patient at home. The dose and course are decided by the doctor.

Uses of Hemorise 500 IV

It is intended for people who do not tolerate iron taken by mouth or who have not had a satisfactory response to oral iron. Hemorise 500 IV is used to treat iron deficiency anemia in adults who have intolerance to oral iron or an unsatisfactory response to oral iron, and in adults with non-dialysis dependent chronic kidney disease. It helps replace iron stores in the body. Ask your doctor whether it is right for your condition.

How to use Hemorise 500 IV

You should not self-administer it. Do not inject it yourself unless a doctor has shown you how. Hemorise 500 IV is given as an injection by a healthcare professional. Take Hemorise 500 IV 500 mg/10 ml injection by mouth as directed by your doctor. If you miss a dose, ask your doctor or pharmacist what to do. Follow the doctor's instructions about follow-up and any tests.

Side effects of Hemorise 500 IV

Serious allergic-type reactions, including anaphylactic-type reactions, have been reported and can be life-threatening. Some people may have nausea, vomiting, headache, dizziness, flushing, itching, rash, hives, wheezing, constipation, low blood pressure, a bitter taste, injection site discolouration, or changes in blood phosphorus and liver enzyme tests. Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.

Safety and precautions

Breastfeeding mothers, people with other medical conditions, and those taking other medicines should ask the doctor first. It is pregnancy category C, so ask your doctor whether it is suitable if you are pregnant, planning pregnancy, or breastfeeding. Tell the doctor about allergies, pregnancy, breastfeeding and other medicines before treatment. Tell your doctor before treatment if you have had an allergic reaction to iron products or to any ingredient in this injection.

Frequently asked questions

What does Hemorise 500 IV treat?

It is intended for people who do not tolerate iron taken by mouth or who have not had a satisfactory response to oral iron. Hemorise 500 IV is used to treat iron deficiency anemia in adults who have intolerance to oral iron or an unsatisfactory response to oral iron, and in adults with non-dialysis dependent chronic kidney disease.

How is Hemorise 500 IV used?

You should not self-administer it. Do not inject it yourself unless a doctor has shown you how.

What should I watch for while using Hemorise 500 IV?

Serious allergic-type reactions, including anaphylactic-type reactions, have been reported and can be life-threatening. Some people may have nausea, vomiting, headache, dizziness, flushing, itching, rash, hives, wheezing, constipation, low blood pressure, a bitter taste, injection site discolouration, or changes in blood phosphorus and liver enzyme tests.

Who should be careful with Hemorise 500 IV?

Breastfeeding mothers, people with other medical conditions, and those taking other medicines should ask the doctor first. It is pregnancy category C, so ask your doctor whether it is suitable if you are pregnant, planning pregnancy, or breastfeeding.

Indications

Ferric Carboxymaltose is indicated for the treatment of iron deficiency anemia in adult patients-
  • Who have intolerance to oral iron or have had unsatisfactory response to oral iron
  • Who have non-dialysis dependent chronic kidney disease.

Pharmacology

Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin Macrophage engulf FCM from blood and control iron release. Transferrin saturates and, Iron into the liver, spleen and Bone marrow.

Dosage & Administration

For patients weighing 50 kg or more: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 750 mg for a total cumulative dose not to exceed 1500 mg of iron per course.

For patients weighing less than 50 kg: Give Ferric Carboxymaltose in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course.

The dosage of Ferric Carboxymaltose is expressed in mg of elemental iron. Each mL of Ferric Carboxymaltose contains 50 mg of elemental iron. Ferric Carboxymaltose treatment may be repeated if iron deficiency anemia reoccurs.

Administer Ferric Carboxymaltose intravenously, either as an undiluted slow intravenous push or by infusion. When administering as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. When administered via infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.

When added to an infusion bag containing 0.9% Sodium Chloride Injection, USP, at concentrations ranging from 2 mg to 4 mg of iron per mL, Ferric Carboxymaltose solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.

Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of Ferric Carboxymaltose is intended for single use only. Any unused drug remaining after injection must be discarded.

Avoid extravasation of Ferric Carboxymaltose since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation. If extravasation occurs, discontinue the Ferric Carboxymaltose administration at that site.

Interaction

There are no known drug interactions and none well documented.

Contraindications

Hypersensitivity to any of its components.

Side Effects

Nausea, Hypertension, Flushing, Decreased blood phosphorus, Dizziness, Vomiting, Pruritus, Rash, Urticaria, Wheezing, Injection site discoloration, Headache, Increased alanine aminotransferase), Dysgeusia, Hypotension, Constipation, Serious anaphylactic/anaphylactoid reactions

Pregnancy & Lactation

Pregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Precautions & Warnings

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus, rash, urticaria, wheezing, or hypotension may occur.

Hypertension: 
Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Ferric carboxymaltose administration.

Storage Conditions

Do not store above 30°C. Do not freeze.

Alternative brands of Ferric Carboxymaltose

Other brands with the same generic name, cheapest first.

See all 15 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.